Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company has made significant progress in developing a broad portfolio of RAS(ON) inhibitors across multiple disease settings.
Daraxonrasib, a pioneering RAS(ON) multi-selective inhibitor, has already shown an unprecedented clinical profile in various combinations. Consequently, the company is enrolling patients in the US for a Phase 3 trial of RASolve 301 in Non-Small Cell Lung Cancer (NSCLC).
On the other hand, Zoldonrasib, an innovative RAS(ON) G12D-selective covalent inhibitor, has shown a highly differentiated safety and tolerability profile.
“We expect a pivotal readout from RASolute 302 in the first half of 2026, which represents an important milestone for daraxonrasib, for patients with pancreatic cancer, and for our RAS(ON)-targeting strategy overall,” Goldsmith said.
Revolution Medicines exited 2025 in a strong financial position with $2 billion in cash, cash equivalents, and marketable securities. Research and development expenses surged to $294.9 million in the fourth quarter of 2025 from $188.1 million in the fourth quarter of 2024. The increase was driven by higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib. Full-year R&D expense totaled $987.3 million compared to $592.2 million in 2024
Net loss in the fourth quarter nearly doubled to $364.9 million, compared with $194.6 million in the same quarter of the prior year. The full-year 2025 net loss came in at $1.1 billion, compared to $600.1 million in 2024.
Revolution Medicines, Inc. is a clinical-stage oncology company focused on discovering and developing targeted therapies for RAS-addicted cancers, which represent roughly 30% of new cancer diagnoses.
READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.
